Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | DGKA | P23743 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 4/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8764544 | 1.00 | MAPT (0.53) | MAPTCNR1CNR2TSHRDGKA | |
| SCHEMBL15366242 | 1.00 | MAPT (0.53) | MAPTCNR1CNR2TSHRDGKA | |
| SCHEMBL1878843 | 0.93 | MAPT (0.56) | MAPTCNR1CNR2TSHRHCAR2 | |
| SCHEMBL9106059 | 0.90 | MAPT (0.54) | MAPTDGKAPPARGPPARAFAAH | |
| SCHEMBL9111129 | 0.90 | MAPT (0.54) | MAPTDGKAPPARGPPARAFAAH | |
| SCHEMBL31404911 | 0.89 | CNR1 (0.58) | MAPTCNR1CNR2DGKAPPARG | |
| SCHEMBL31404901 | 0.87 | CNR1 (0.57) | MAPTCNR1CNR2TSHRDGKA | |
| SCHEMBL7026430 | 0.87 | CNR1 (0.57) | MAPTCNR1CNR2TSHRDGKA | |
| SCHEMBL10783818 | 0.85 | TSHR (0.49) | MAPTTSHRDGKAPPARGPPARA | |
| SCHEMBL7029180 | 0.85 | TSHR (0.49) | MAPTTSHRDGKAPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2695613-A1 | ANALGESIC | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2014-02-12 | — | — | EP | disclosed |
| EP-2695613-A1 | ANALGESIC | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2014-02-12 | — | — | EP | disclosed |
| EP-2671578-A1 | PROPHYLACTIC OR THERAPEUTIC DRUG FOR PERIPHERAL NEUROPATHY CAUSED BY ANTICANCER AGENT | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2013-12-11 | — | — | EP | disclosed |
| US-20130296425-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR A PERIPHERAL NERVE DISORDER INDUCED BY ANTI-CANCER AGENTS | NAGOYA INDUSTRIAL SCIENCE RESEARCH INSTITUTE (JP) | 2013-11-07 | — | — | US | disclosed |
| US-20130296426-A1 | ANALGESIC | NAGOYA INDUSTRIAL SCIENCE RESEARCH INSTITUTE (JP) | 2013-11-07 | — | — | US | disclosed |
| US-20130296425-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR A PERIPHERAL NERVE DISORDER INDUCED BY ANTI-CANCER AGENTS | NAGOYA INDUSTRIAL SCIENCE RESEARCH INSTITUTE (JP) | 2013-11-07 | — | — | US | disclosed |
| US-20130296426-A1 | ANALGESIC | NAGOYA INDUSTRIAL SCIENCE RESEARCH INSTITUTE (JP) | 2013-11-07 | — | — | US | disclosed |
| US-20130296426-A1 | ANALGESIC | NAGOYA INDUSTRIAL SCIENCE RESEARCH INSTITUTE (JP) | 2013-11-07 | — | — | US | disclosed |
| US-20130296425-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR A PERIPHERAL NERVE DISORDER INDUCED BY ANTI-CANCER AGENTS | NAGOYA INDUSTRIAL SCIENCE RESEARCH INSTITUTE (JP) | 2013-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296425-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR A PERIPHERAL NERVE DISORDER INDUCED BY ANTI-CANCER AGENTS | ALOX5, CPT1B, PMP22 | MAPT 4360/4885CNR1 187/4885CNR2 130/4885 |
| US-20130296426-A1 | ANALGESIC | CNTN1, SHARPIN, HCAR2 | MAPT 2871/4885CNR1 631/4885CNR2 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.